MS1819 lipase, Phase IIa

• Non-systemic, yeast derived recombinant enzyme
• Oral non-systemic capsule for treatment of exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis (CP) and cystic fibrosis (CF)
• Demonstrates superior in vitro characteristics (i.e. high potency, activity in long chain fats, stability in protease and bile salt environments), eliminates pork viral contamination risk
• Phase IIa in vivo safety and efficacy profile shows promise to improve on standard porcine-derived therapy

AZX1103 beta lactamases, preclinical

• Oral, non-systemic medicine to act locally in the GI tract to prevent nosocomial (hospital-acquired) infections by resistant bacterial strains induced by parenteral administration of β-lactam antibiotics.